Cancer of the cervix and uterus have been treated using Iridium 192(Varisource, Varian UK). Since clinical work began in 1996, 5 year cervical cancer survival data have been calculated. These are:
These data compare well with 40% from data published from a UK study and 55% from a European FIGO study. Clinical aspects of treatment planning are presented. Future developments, in line with ESTRO recommendations are outlined.
Plane JH and Rathmell AJ. 5 year survival data for cancer of the cervix using a high dose rate Iridium 192 afterloader. Poster Presentation. GEC-ESTRO Brachytherapy Meeting, Montpellier, 10-12 May, 2007.
Jim H. Plane, Cleveland Unit, Middlesbrough. Tel: +44 (0)1642-854-778.
Regional Medical Physics Department, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK.
Tel: +44 (0)191-233-6161 E-mail: webmaster@rmpd.org.uk Web: http://www.rmpd.org.uk
By using this site you agree to our Terms and Conditions of Use. Please read our legal page.
Regional Medical Physics Department, a Clinical Directorate of the Newcastle upon Tyne Hospitals NHS Foundation Trust.
Copyright ©1999-2008 All Rights Reserved. Revised 7 November, 2008.
